1-3 of 3
Isabelle Sudaka
Close
Sort by
Journal Articles

Comparison of Risk Stratification Tools (ELN-2022, ELN-2017, Lindsley et al. , Papaemmanuil et al. and ALFA classifier) in Predicting Outcomes of Patients with Acute Myeloid Leukemia

Alexandre Iat, Michael Loschi, Sami Benachour, Anne Calleja, Edmond Chiche, Isabelle Sudaka, Danièle Aquaronne, Corinne Ferrero, Patricia Brugel, Lea Ryffel, Laurène Fenwarth, Alice Marceau, Elise Fournier, Berengere Dadone, Thomas Cluzeau
Journal: Blood
Blood (2022) 140 (Supplement 1): 9105–9106.
https://doi.org/10.1182/blood-2022-164583
Published: 2022
Journal Articles

Unmodified Dose of Azacitidine Plus Venetoclax Regimen without Drug Interactions during the First Cycle Leads to Similar Outcomes between Viale-a Clinical Trial and Real-Life in Acute Myeloid Leukemia

Bochra Sedaki, Alexandre Iat, Michael Loschi, Sami Benachour, Edmond Chiche, Lea Ryffel, Patricia Brugel, Isabelle Sudaka, Danièle Aquaronne, Corinne Ferrero, Berengere Dadone, Thomas Cluzeau
Journal: Blood
Blood (2022) 140 (Supplement 1): 11718–11719.
https://doi.org/10.1182/blood-2022-164608
Published: 2022
Journal Articles

Prognostic Factors of Response to Erythropoiesis Stimulating Agents (ESA) Treatment in Non RBC Transfusion Dependent Lower Risk MDS. Preliminary Results of a French and Italian Study (on behalf of the GFM and FISM).

Sophie Park, Gina Zini, Valérie Andrieu, Alessandro Levis, MD, Daniela Gioia, PhD, Eliane Duchayne, MD, PhD, BSc, Antonella Poloni, MD, Enrico Balleari, MD, Marco Calabrese, Isabelle Sudaka, Virginie Siguret, Martine Guesnu, Olivier Kosmider, MD, PhD, Michaela Fontenay, MD, PhD, Alessandro Sanna, MD, Pierre Lemaire, Odile Beyne-Rauzy, Lionel Ades, MD, PhD, Laurence Legros, MD, PhD, Paolo Danise, MD, Pellegrino Musto, Pierre Fenaux, MD, PhD, Francois Dreyfus, Valeria Santini, MD
Journal: Blood
Blood (2012) 120 (21): 2814.
https://doi.org/10.1182/blood.V120.21.2814.2814
Published: 2012